<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141959</url>
  </required_header>
  <id_info>
    <org_study_id>FHCRC-2373.00</org_study_id>
    <secondary_id>IR-7093</secondary_id>
    <secondary_id>R01HL091744-02S1</secondary_id>
    <nct_id>NCT01141959</nct_id>
  </id_info>
  <brief_title>Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients</brief_title>
  <official_title>Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are interested in identifying patient-specific factors related to donor
      chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from
      haploidentical donors. We will look how patients' bodies break down and immediately respond
      to cyclophosphamide, fludarabine and mycophenolate mofetil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Donor T-cell chimerism</measure>
    <time_frame>Day 28 post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products</measure>
    <time_frame>1 week before through 3 weeks after transplant</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Multiple Myeloma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hematopoeitic cell transplant patients with haploidentical donors receiving
        cyclophosphamide, fludarabine and mycophenolate mofetil.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to receive nonmyeloablative conditioning which includes fludarabine

          -  Scheduled to receive a haploidentical graft

          -  Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate
             mofetil (MMF) or enteric-coated mycophenolic acid

          -  Age &gt;18 years at the time of enrollment

        Exclusion Criteria:

          -  Diagnosed with an immunodeficiency disorder, including HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannine McCune, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>fludarabine</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

